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Abstract
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We previously discovered that phytonutrient genistein rapidly activates cAMP signaling in β-cells
and improving islet mass in diabetic mice. However, the mechanism underlying these actions of
genistein is still unclear. Here, we show that pharmacological or molecular inhibition of Gαs
blocked genistein-stimulated adenylate cyclase activity in plasma membrane and intracellular
cAMP production in INS1 cells and islets. Further, genistein stimulation of cAMP generation was
abolished in islets exposed to a specific GPR30 inhibitor G15 or islets from GPR30 deficient
(GPR30−/−) mice. In vivo, dietary provision of genistein (0.5 g/kg diet) significantly mitigated
streptozotocin-induced hyperglycemia in male WT mice, which was associated with improved
blood insulin levels and pancreatic islet mass and survival, whereas these effects were absent in
Gpr30−/− mice. Genistein treatment promoted survival of INS1 cells and human islets chronically
exposed to palmitate and high glucose. At molecular level, genistein activated CREB
phosphorylation and subsequently induced Bcl-2 expression, and knockdown of CREB diminished
the protective effect of genistein on β-cells induced by lipoglucotoxicity. Finally, deletion of
GPR30 in β-cells or islets ablated genistein-induced CREB phosphorylation and its cytoprotective
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effect. These findings demonstrate that genistein is a survival factor for β-cells via GPR30initiated, Gαs-mediated activation of CREB.
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1. Introduction
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It is estimated that over 30.3 million or 9.4% of people in the US presently suffer from
diabetes, and 57 million people have pre-diabetes [1]. While the availability of novel drugs,
techniques, and surgical intervention has improved the survival rate of individuals with
diabetes, the prevalence of diabetes is still rising in the U.S., with the number of people with
diabetes projected to double by 2025 [2]. Type 2 diabetes (T2D) is a result of chronic insulin
resistance and progressive loss of β-cell mass and function [3]. In experimental animals and
humans, obesity is a leading pathogenic factor for developing insulin resistance, and insulin
resistance will progress to T2D when β-cells are unable to secret adequate amount of insulin
to compensate for decreased insulin sensitivity, which is largely due to insulin secretory
dysfunction and significant loss of functional β-cells [4, 5]. Indeed, those individuals with
T2D always manifest increased β-cell apoptosis and reduced β-cell mass [5–7]. Sustained
hyperlipidemia and hyperglycemia in β-cells play an important role in contributing to β-cell
apoptosis and dysfunction, thereby leading to the deterioration of glycemic control and the
overt development of T2D [8, 9]. As such, the search for agents that promote β-cell survival
may provide an effective strategy to prevent the onset of diabetes [10].
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Genistein is a flavonoid compound present in legumes and Chinese herbal medicines
Genista tinctoria Linn and Sophora subprostrala Chun. It is widely used as a dietary
supplement in the U.S. for various presumed health benefits [11–13]. Genistein has been
previously investigated for its potential beneficial effects on cancer treatment, cognitive
function, and cardiovascular and skeletal health, with a primary focus on exploring its
potential hypolipidemic, anti-oxidative and estrogenic effects [11–13]. While studies on
whether genistein alone has an effect on diabetes are limited, available data showed that
administration of genistein-containing soy products lowered plasma glucose in diabetic
animals [14, 15] and in humans [16, 17]. Genistein has been reported to exhibit antioxidant
activity [18, 19]. However, this effect of genistein is achieved only at concentrations ranging
from 25-100 μM, which are well beyond those achievable through dietary ingestion of
genistein supplement in both humans and rodents. Thus, the mechanism of genistein’s action
as a potential anti-diabetic agent is still unknown. We recently observed for the first time that
genistein at physiologically achievable concentrations (0.1-5 μM) activated cAMP signaling
by inducing adenylate cyclase (AC) activity in β-cells and islets [20]. We further
demonstrated that dietary intake of genistein preserved β-cell mass and mitigated diabetes in
mice [21]. In the present study, we investigated whether genistein directly promotes β-cell
survival and prevents diabetes by targeting the G-protein-coupled receptor (GPCR)-mediated
signaling pathway.
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2. Research design and Methods
2.1. Materials and Reagents
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Cell culture medium, supplements, palmitate, fatty acid-free bovine serum albumin (BSA),
H89, mellittin, and protease and phosphatase inhibitor cocktails were from Sigma (St. Louis,
MO); genistein (purity≥99.0%) was from LC Laboratories (Woburn, MA); ICI 182,780
(ICI), 17β-estradiol (E2), and G15 were from Tocris Biosciences (Bristol, UK); insulin
ELISA kits were obtained from Crystal Chemical Inc. (Chicago, IL); cell viability and
caspase-3 assay kits, pRL luciferase control vector, and dual luciferase assay system were
purchased from Promega (Madison, WI); cyclic AMP EIA kits were from Cayman
Chemical Company (Ann Arbor, MI); terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay kits were from Trevigen Inc. (Gaithersburg，MD); the active form
of the caspase −3 antibody was from BD Biosciences (San Jose, CA); the rabbit polyclonal
anti-insulin antibody was from Abcam (Cambridge, MA); antibodies for phospho-CREB
(ser133), CREB, and β-actin were from Cell Signaling Technology (Beverly, MA);
nitrocellulose membranes and protein assay kits were from Bio-Rad (Hercules, CA); CREB
ShortCut® siRNA, scramble sequence of siRNA and transfection reagents were from New
England Biolabs (Ipswich, MA); anti-GPR30, anti-Gαs, shGαs lentiviral particles, and
GPR30 siRNA (rats) were from Santa Cruz Biotechnology (Santa Cruz, CA); a reporter
plasmid containing a promoter region of the Bcl-2 gene linked to a firefly luciferase gene
(Bcl-2-Luc) was a gift of Dr. Linda M. Boxer, Stanford University); a reporter plasmid
containing multiple copies of a consensus cAMP responsive element (CRE)-binding
sequence fused to a TATA-like promoter region upstream of the gene for firefly luciferase
(CRE-luc) was from BD Clontech, CA; the plasmid transfection reagent was from
Invitrogen, CA; the ImmPRESS anti-rabbit Ig (peroxidase) polymer detection kit, vector
NovaRED peroxidase substrate, and vector SG peroxidase substrate were from Vector
Laboratories (Burlingame, CA). Stock solutions of genistein and E2 at 20 mM dissolved in
dimethyl sulfoxide (DMSO) were stored at –20 °C.
2.2. Cell and human islet culture

Author Manuscript

INS1 cells (provided by Dr. Pierre Maechler, University of Geneva Medical School) were
cultured as previously described [22]. Human islets were supplied through the Integrated
Islet Distribution Program (City of Hope Medical Center, Duarte, CA). The islet purity and
viability was over 90%. The islets were maintained in CMRL-1066 medium containing 10%
FBS. Palmitate was dissolved in medium containing 7% fatty acid-free BSA, sonicated, and
sterile-filtered (final fatty acid/BSA molar ratio=6.6) [23]. For control experiments,
palmitate-free BSA was prepared in the same way as stated above. For examining the effects
of genistein on CREB phosphorylation, INS1 cells or islets were pre-incubated with Krebs
Ringer Bicarbonate buffer for 20 min followed by treatment with genistein or vehicle for 30
min. In some experiments, INS1 cells or islets were preincubated with estrogen (E2)
receptor (ER) antagonist ICI 182,780 (ICI; 10 μM), PKA inhibitor H89 (10 μM), Gαs
inhibitor mellittin (M; 5 μM), GPR30 antagonist G15 (5 μM), or vehicle (DMSO) for 30 min
before addition of genistein.
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2.3. AC and intracellular cAMP measurements
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For measuring AC activity, the plasma membranes from INS1 cells were isolated by
differential centrifugation [24]. The membranes were pre-incubated with GDPβS (100 μM),
Gαs antibody (1:200), non-immune IgG, or vehicle for 30 min at 25°C, followed by addition
of genistein (2.5 μM), GLP-1 (20 nM), forskolin (5μM), or vehicle, for 10 min. AC activity
was then measured by determining cAMP production as previously described [24]. For
intracellular cAMP measurements, islets were treated with genistein (5 μM) for 20 min.
Intracellular cAMP levels were measured by an EIA kit [20]. Data were normalized to the
cellular protein concentration in the same samples.
2.4. Immunoblot analysis
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Equal amounts of protein (50 μg) from cell extracts were subjected to immunoblot analysis
as previously described [21]. Membranes were first probed with an antibody against Gαs,
GPR30, Bcl-2, or phospho-CREB (p-CREB). The immunoreactive proteins were detected
by chemiluminescence. Nitrocellulose membranes were then stripped and reprobed with
antibodies against CREB or β-actin. The protein bands were digitally imaged for
densitometric quantitation with Image Lab instrument(Bio-Rad). The expression of p-CREB
and Bcl-2 was normalized to that of total CREB and β-actin, respectively, and expressed as a
fold increase over the control.
2.5. Transfection assays

Author Manuscript

INS1 cells were grown in a 24-well plate until 50% confluence. To determine whether
genistein activates cAMP-regulated transcription, cells were co-transfected with 0.25 μg
CRE-Luc reporter plasmid and 5 ng pRL reporter control vector per well using
Lipofectamine 2000 transfection reagent according to the manufacturer’s protocol. To
examine whether genistein enhances Bcl-2 transcription, cells were co-transfected with 0.5
μg Bcl-2-Luc vector and 1 ng pRL reporter plasmid per well. After transfection, cells were
incubated with complete RPMI1640 medium for 24 h, and then treated with genistein or
vehicle for 16 h for CRE-luc-transfected cells, or 24 h for Bcl-2-luc-transfected cells.
Luciferase activity, normalized to pRL activity in the cell extracts was then determined with
a dual luciferase reporter assay system.
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For knockdown of CREB, INS1 cells were transfected with a heterogeneous mixture of
target-specific CREB siRNA (50 nM) or corresponding amounts of scrambled siRNA using
siRNA transfection reagents according to the manufacturers’ protocols. After 48 h of
transfection, cells were incubated with or without genistein for 30 min for immunoblot
analysis of CREB protein expression, or incubated with palmitate (0.5 mM) and high
glucose (HG, 20 mM) in the presence or absence of genistein (5 μM) for 72 h followed by
apoptosis assays. To delete GPR30, INS1 cells were transfected with 100 nM GPR30 siRNA
or scrambled siRNA in serum- and antibiotic-free media for 16 h using Lipofectamine 2000
transfection reagent. Cells were then cultured in complete DMEM for 24 h, followed by
treatment with 5 μM genistein or vehicle.
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2.6. Cell apoptosis assays
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INS1 cells or islets were cultured in complete RPMI-1640 medium with or without 0.5 mM
palmitate and HG in the absence or presence of genistein (0.1, 1, and 10 μM) for 72 h, with
genistein supplemented media replaced after 48 h. Cellular apoptosis was measured with a
TUNEL-based quantitative apoptotic assay kit. For measuring cellular caspase-3 activity,
cells or islets were cultured under the above glucolipotoxic condition with or without
genistein for 48 h. The caspase-3 activity in the cell lysates was measured using an assay kit
and normalized to the cellular protein concentration, measured with a Bio-Rad assay kit.
2.7. Animals and treatments
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WT or Gpr30−/− mice (breeding colony provided by Dr. Deborah Clegg, UT Southwestern)
were housed in a room maintained on a 12h light/dark cycle under constant temperature (22–
25° C) with ad libitum access to food and water. Homozygosity was confirmed via
quantitative RT-qPCR. When mice were 7-mo old, WT and Gpr30−/− male mice were
divided into 4 groups with their initial body weight and blood glucose balanced among
groups. The mice were then fed a phytoestrogen-free high-fat diet (HFD, 45% kcal fat) or
HFD supplemented with 0.05% genistein. Body weight and food intake were recorded
weekly. This genistein dosage was used (approximately a human intake of 25-200 mg/day)
because it is within the range that humans can realistically consume through taking
supplements [25]. After 4 wks of treatment, mice were injected intraperitoneally
streptozotocin (STZ) dissolved in 0.1 mM cold sodium citrate buffer (pH 4.5) at 40 mg/kg
daily for 3 consecutive days. Control mice were injected the same amount of vehicle. After
this procedure, mice were remained on the same dietary treatment for 9 wks for the
following metabolic measurements. Body weight and food intake were recorded weekly. The
protocol of this study was approved by the Institutional Animal Care and Use Committee at
Virginia Tech (protocol number: 11-176-HNFE).
2.8. Metabolic measurements
At the beginning of the experiment, fasting (12h) blood glucose was measured in tail vein
blood sample using a glucometer (Kroger). Following STZ injection, blood glucose was
measured weekly to assess the onset of hyperglycemia (non-fasting blood glucose >250
mg/dl) [26]. Plasma insulin concentrations were measured by ELISA (Crystal Chem, IL).
Glucose tolerance and insulin sensitivity were assessed as previously described [21]. Fasting
plasma total cholesterol and triacylglycerides were measured in triplicate using a Pointer
180 Analyzer (Pointe Scientific, Canton, MI) as described [27].
2.9. Immunohistochemistry and islet morphometry
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At the end of the feeding study, mouse pancreata were collected and fixed as previously
described [21]. A series of tissue sections (5-μm thickness) were prepared by AML
Laboratory (Baltimore, MD), and immuno-stained to determine β-cell mass and apoptosis.
The β-cell area was measured using images acquired from serial insulin-stained pancreatic
sections (100 μm interval). The β-cell mass were calculated as previously described [21].
Apoptotic β-cells were detected by double labeling the sections with antibodies against
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activated caspase-3 and insulin using an ImmPRESS™ detection system as we previously
described [28].
2.10. Statistical analysis
Data were analyzed with one-way ANOVA using SigmaPlot software. Treatment differences
were subjected to Tukey’s test. A p-value < 0.05 was considered significant.

3. Results
3.1. Genistein activation of cAMP signaling is mediated via Gαs in β-cells

Author Manuscript

We recently found that genistein rapidly activates AC in β-cells [20]. AC activity is
stimulated by G-protein α-subunit (Gαs), which is an important regulator of β-cell mass and
function [29]. We found that genistein activation of AC in plasma membranes of β-cells was
inhibited by GDPβS (Fig. 1A), which blocks the exchange of a GDP for a GTP and thereby
inhibits the activation of G-proteins [30]. Further, pre-incubation of the plasma membranes
from INS1 cells with anti-Gαs, which neutralizes and thereby blocks Gαs activation, ablated
genistein activation of AC activity (Fig. 1B). Interestingly, genistein showed similar potency
in inducing AC activity as glucagon-like-peptide-1 (GLP-1), a potent incretin that activates
Gαs/AC signaling via its receptor β-cells. The effect of GDPβS or anti-Gαs on genisteininduced AC activation is specific because they did not influence forskolin-induced AC
activity.
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To examine whether Gαs also mediates genistein-stimulated cAMP production in β-cells
and islets, INS1 cells or human islets were pre-incubated in the absence or presence of the
Gαs inhibitor, mellittin (5 μM), for 30 min [31], followed by addition of genistein (5μM) or
vehicle for 20 min. Inhibition of Gαs with mellittin blocked genistein-stimulated cAMP
production in INS1 cells (Fig. 1C) and human islet cells (Fig. 1D). We then utilized shRNAexpressing lentiviral particles to suppress Gαs expression in human islets, in order to further
investigate whether Gαs mediates genistein-stimulated cAMP production in pancreatic
islets. Consistently, infection of human islets with an Gαs-specific shRNA-expressing
lentivirus ablated the expression of Gαs protein (Fig. 1E), and subsequently diminished
genistein-triggered cAMP production (Fig. 1F), whereas the scrambled shRNA did not affect
Gαs protein expression and genistein/cAMP signaling in the islets. Combined, these results
provide evidence that Gas is essential in mediating genistein/cAMP signaling in β-cells.
3.2. Genistein acts through GPR30

Author Manuscript

Activation of AC could be linked to Gαs-coupled receptors [32] and genistein may bind to
GPR30, a membrane-associated GPCR, in cancer cells [33]. We thus reasoned that genistein
activation of cAMP signaling may be mediated via this receptor. We first confirmed that
GPR30 protein is highly expressed in clonal rodent β-cells and human and mouse islets (Fig.
2A). Incubation of INS1 cells with G15, a specific GPR30 inhibitor, diminished genisteinstimulated cAMP production (Fig. 2B). Knockdown of Gpr30 with siRNA (Fig. 2C) greatly
ablated genistein-stimulated cAMP production in INS1 cells, whereas scrambled siRNA had
no such an effect (Fig. 2D). Furthermore, genistein stimulated cAMP generation in isolated
WT mouse islets, but this genistein action was absent in Gpr30−/− islets (Fig. 2E). The
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deletion of GPR30 in islets from Gpr30−/− mice was confirmed by western blot analysis of
GPR30 protein expression (Fig. 2F).
3.3. The anti-diabetic action of genistein in mice is mediated via GPR30

Author Manuscript

We next investigated whether GPR30 mediates the anti-diabetic effect of genistein in vivo.
Before STZ injection, genistein had no effect on body weight gain, food intake or nonfasting blood glucose levels in both WT and Gpr30−/− mice (data not shown). As expected,
STZ injection induced hyperglycemia in both WT and Gpr30−/− mice (Fig. 3A and B). We
observed that WT diabetic mice fed a genistein supplemented HFD had significantly lower
blood glucose levels as compared to HFD-fed WT diabetic mice (Fig. 3A), suggesting that
genistein mitigated STZ-induced hyperglycemia. However, genistein failed to lower blood
glucose levels in STZ-induced Gpr30−/− diabetic mice (Fig. 3B). Fasting blood glucose
levels were not greatly increased by STZ injection or significantly modulated by genistein
treatment (data not shown), indicating that STZ-induced elevation of blood glucose in our
models is mainly due to a destruction of pancreatic β-cells, leading to deficiency of glucosestimulated insulin secretion. Consistently, genistein significantly improved glucose tolerance
(Fig. 3C and D) and postprandial circulating insulin levels (Fig.3E) in WT mice but not in
Gpr30−/− mice (data not shown). Genistein had no effects on plasma lipid profiles (data not
shown) and whole body insulin sensitivity in both WT (Fig. 3F) and Gpr30−/− (data not
shown) mice.
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Next, we examined whether genistein treatment preserved β-cell mass in WT diabetic mice.
STZ administration severely decreased β-cell mass and disrupted the islet architecture.
However, genistein-treated diabetic mice had significantly more islet β-cell mass and
improved islet structure (Fig. 3G and H) concomitant with greater insulin content in the
pancreas (Fig. 3I) as compared to control diabetic mice. Consistently, genistein reduced islet
β-cell apoptosis, as determined by double immunolabeling of insulin and the activated
caspase-3 (Fig. 3J and K), a key protease involved in the terminal steps of cell apoptosis.
These results suggest that genistein improvement of hyperglycemia in STZ-induced obese
diabetic mice is primarily due to GPR30-dependent protection of islet function.
3.4. Genistein prevents apoptosis of INS1 cells and islets exposed to glucolipotoxicity

Author Manuscript

To determine whether genistein directly promotes survival of β-cells, we first evaluated
whether genistein protects INS1 cells exposed to excessive amounts of saturated fatty acids
and glucose (glucolipotoxicity), which are believed to cause β-cell apoptosis and impair its
function, thereby contributing to the pathogenesis of T2D [23]. Incubation of INS1 cells
with palmitate (0.5 mM) and HG for 72 h significantly increased apoptosis. However, cotreatment with genistein dose-dependently prevented cell apoptosis induced by chronic
glucolipotoxicity (Fig. 4A), with 1 μM genistein exerting a significant effect. In parallel to
decreased apoptosis, the cellular caspase-3 activity was markedly increased in INS1 cells
under glucolipotoxicity, which was significantly reduced by genistein treatment (Fig. 4B). In
consistent with this cytoprotective effect in INS1 cells, genistein treatment also promoted
survival of mouse (Fig. 4C and D) and human (Fig. 4E and 4F) islets chronically exposed to
palmitate (0.5 mM) and HG (20 mM). To test whether genistein modulates anti-apoptotic
Bcl-2 expression, which could be a mechanism through which genistein promotes islet cell
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survival, we incubated INS1 cells with genistein for 24 h, and found that genistein greatly
induced Bcl-2 protein expression (Fig. 4G), which was accompanied with increased Bcl-2
promoter activity (Fig. 4H) as determined by a reporter gene assay, suggesting that genistein
may regulate Bcl-2 expression at the transcriptional level in β-cells. Collectively, these
results demonstrate that genistein directly promotes islet β-cell survival.
3.5. The anti-apoptotic effect of genistein is independent of estrogen receptor (ER)
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As genistein may have weak estrogenic effects on some tissues, and previous studies showed
that E2 can promote β-cell survival [34, 35], we examined whether genistein promotion of
islet survival was mediated via ERs. Genistein or E2 alone reduced human islet cell
apoptosis (Fig. 5A). However, incubation of human islets with ICI182,780, a specific
antagonist of ERα and ERβ, reduced the cytoprotective effect of E2 by 70%, but had no
effect on genistein-mediated action. Moreover, daidzein, an analogue of genistein that is
essentially inactive as an ER ligand [36], also prevented β-cell apoptosis (Fig.5B). These
results indicate that genistein actions in β-cells are likely independent of ERα- and ERβmediated signaling machinery.
3.6. The cytoprotective effect of genistein in β-cells depends on GPR30-mediated
activation of CREB
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Author Manuscript

To investigate the underlying mechanism through which genistein promotes β-cell survival,
we first determined whether genistein treatment activates CREB, an important β-cell
survival factor [37]. Exposure of INS1 cells (Fig. 6A) and human islets (Fig. 6B) to
genistein for 30 min activated CREB, a pattern that is consistent with its effects on cAMP
production and cell survival. Pretreatment of cells with PKA inhibitor H89 abolished
genistein-induced CREB phosphorylation (Fig. 6C), suggesting that PKA mediates the
genistein-stimulated phosphorylation of CREB. We then tested whether the activation of
CREB by genistein is sufficient to affect transcription of cAMP-regulated genes, which
include Bcl-2. Genistein at as low as 1 μM concentration significantly stimulated CREmediated luciferase activity in INS1 cells, with 10 μM dose inducing a more than 1.5-fold
increase in transcription over the control (Fig. 6D). Next, we used RNA interference to
examine whether genistein protection of β-cell apoptosis is mediated via activation of
CREB. Transfection of β-cells with CREB-specific siRNA greatly reduced CREB protein
expression, whereas the scrambled siRNA did not affect CREB expression (Fig. 6E).
Accordingly, disruption of CREB expression with siRNA diminished genistein-induced
CREB phosphorylation (Fig. 6F), Bcl-2 protein expression (Fig. 6G), and its cytoprotective
effect (Fig. 6H) in INS1 cells, whereas transfection with a scrambled siRNA had no effect
on genistein-mediated actions. To further investigate whether genistein activation of CREB
is mediated via GPR30, we transfected INS1 cells with siRNA of GPR30 or its scrambled
control. Knockdown of GPR30 mRNA, which greatly reduced its protein expression (Fig.
2C), ablated genistein-stimulated CREB phosphorylation without affecting total CREB
expression in INS1 cells (Fig. 6I). Similarly, genistein stimulated CREB phosphorylation
(Fig. 6J) and protected against apoptosis (Fig. 6K) of WT islets exposed to palmitate and
HG, but these effects were absent in Gpr30−/− islets. Collectively, these data for the first time
demonstrated that genistein prevents β-cells from apoptosis via GPR30-mediated activation
of CREB.
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4. Discussion
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It has been shown that administration of phytonutrient genistein lowered plasma glucose in
diabetic animals [14, 15] and in humans [16, 17] without affecting insulin sensitivity and fat
metabolism. However, the molecular mechanism of this genistein action is still unclear. In
the present study, we provide evidence for the first time that genistein directly promotes βcell survival via the GPR30/Gα/AC/cAMP/PKA/CREB signaling pathway. Notably, this
finding is physiologically relevant, as the effective doses of genistein (1-10 μM) overlap with
those achievable by dietary intake of genistein supplement, which can achieve the total
plasma genistein levels in the range of 1-7 μM in rodents and humans [13]. Consistent with
these ex vivo findings, we further demonstrated that oral administration of genistein at a
dose that humans can take as dietary supplement [25]. significantly mitigated hyperglycemia
and preserved pancreatic β-cell mass in HFD and STZ-induced obese diabetic mice, an
effect that was abolished in GPR30−/− mice. The significance of our findings is that they
establish a mechanistic basis for the physiological actions of genistein. As the loss of
functional β-cell mass plays a central role in the deterioration of blood glucose control in
both T1D and T2D [5], the search for agents that promote β-cell survival and thereby
preserve functional β-cell mass may provide an effective strategy to prevent the onset of
diabetes. In this regard, genistein may be a safe and low-cost novel natural compound that
can be used to prevent or ameliorate diabetes.
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We recently discovered that genistein is a potent activator of cAMP signaling in islet β-cells
[20]. However, the underlying mechanism of this genistein effect is unclear. In the present
study, we performed a series of complementary experiments with the results indicating that
Gαs activation is the upstream of the genistein elicited cAMP signaling in β-cells. As
genistein activates AC via Gαs in plasma membranes of β-cells, and cell membraneassociated G-proteins are typically activated by GPCRs, we speculated that this genistein
action is transmitted via a membrane-bound receptor, which subsequently activates
intracellular signaling in β-cells. Genistein is known to have an affinity for ERα and ERβ,
although it is unclear whether the physiological effects of genistein observed in vivo are
mediated by these classical ERs. Recent in vitro studies provide evidence that plasma
membrane-associated GPR30 and ER36α, a 36-kDa variant of ERα, are novel membrane
ERs that mediate the membrane-initiated E2 signaling in cancer cells [38, 39]. We chose to
study GPR30 as we showed that it is highly expressed in islets and β-cells consistent with
recent observations [35, 40], whereas ER36α is not detectable. Incubation of β-cells with
G15, a selective GPR30 antagonist that do not interfere with the classical nuclear ER
signaling [41], abolished genistein-stimulated cAMP production. In accordance with this
result, knockdown of GPR30 with siRNA in β-cells or deletion of Gpr30 in mouse islets
greatly reduced genistein-stimulated intracellular cAMP production. These data for the first
time, as to our knowledge, demonstrated that genistein may act on the cell membrane,
eliciting a GPR30-mediated action that leads to the activation of cAMP signaling in β-cells.
Intriguingly, GPR30 is not only expressed in the plasma membrane, but also in the
endoplasmic reticulum and the Golgi complex [42–48], suggesting that GPR30 is an atypical
GPCR. Thus, it is possible that GPR30 is activated intracellularly by genistein and then
translocates to the cell membranes to initiate cellular signaling [45, 46]. While it is still
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unclear how GPR30 exactly interacts with the receptor ligands, which is largely due to the
challenge in purifying active protein from the membrane, it appears that GPR30 can be
activated by structurally diverse molecules such as E2, G1, and ER antagonist tamoxifen and
fulvestrant [49], suggesting that it has large plasticity in accepting ligands. Interestingly, our
unpublished data show that a large group of structurally related flavonoids also potently
activates cAMP-mediated signaling. It may thus be speculated that GPR30 is a common
target for flavonoids, confirmation of which could provide novel insights regarding the
physiological roles of many flavonoids that are ubiquitous in the human diet.
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We further investigated whether GPR30 mediates the antidiabetic action of genistein using
WT and Gpr30−/− mice. In that regard, we used STZ to induce diabetes by directly causing
the destruction of β-cells. We show that oral administration of genistein (50 mg/kg/d)
significantly ameliorated hyperglycemia and glucose intolerance in WT obese diabetic mice,
but these protective effects of genistein were completely absent in Gpr30−/− mice. The
antidiabetic effect of genistein observed in this study might be relevant to humans, because
this dose of genistein used in the present study (equivalent to the human intake of 75-100
mg/day) is within the dose range typically consumed by humans [50]. In addition, we chose
to examine genistein effect in older adult mice (7 mo), because T2D usually occurs at
middle and older age in humans. The diabetic mouse models used in this study were
generated by HFD feeding and 3 mild doses of STZ administration that did not cause
diabetes in chow-fed mice as we previously determined [51]. This mouse model shares the
metabolic characteristics of human T2D with peripheral insulin resistance and reduced βcell mass and function. In the present study, we observed that genistein had no effect on
fasting blood glucose, which is primarily derived from hepatic glucose production [52],
suggesting that gluconeogenesis was not altered by genistein. In line with our recent finding
[21], genistein didn’t alter body weight gain, food intake, fat mass, plasma lipid profile, or
insulin sensitivity, indicating that the blood glucose-lowering effect of genistein is not a
secondary action thereby genistein modulated these variables. In contrast, genistein
treatment significantly improved nonfasting plasma insulin levels in WT diabetic mice.
These results suggest that the improvements in glycemic control by genistein treatment is
primarily due to the improved pancreatic β-cell function, given that STZ induces diabetes by
directly causing β-cell destruction and insulin deficiency. Consistently, dietary
supplementation of genistein to WT mice partially prevented β-cell apoptosis and preserved
islet mass concomitant with higher pancreas insulin content.
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The present study showed that genistein directly promotes β-cell and islet survival. While
genistein can bind to the ERs, and it was reported that E2 can protect islets against stimuliinduced apoptosis via the ER-dependent mechanisms [35], the protective effect of genistein
against glucolipotoxicity-induced apoptosis in β-cells was not dependent on the ERmediated pathway. First, ICI, a highly specific ER inhibitor, blocked E2 effect but did not
affect the cytoprotective effect of genistein in β-cells. In addition, daidzein, an analogue of
genistein that is essentially inactive as an ER ligand [36], also prevented β-cell apoptosis.
Moreover, genistein primarily binds to ERβ but not ERα [36], and a recent study indicates
that E2 acts primarily through ERα to protect β-cells from apoptosis [35]. Indeed, ERα
expression level in the islets is 10-fold higher than that of ERβ [40]. These results further
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imply that genistein may prefer to activate GPR30 in β-cells, while E2 uses ERα to promote
cell survival when all three receptors are present.
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We further revealed that genistein prevents islets from apoptosis via GPR30-mediated
activation of cAMP/PKA/CREB signaling. Our data showed that genistein strongly induced
PKA-dependent, rapid phosphorylation of CREB in INS1 cells and islets, which was
associated with the induction of the expression of the antiapoptotic Bcl-2 protein. Further,
we demonstrated that Bcl-2 is a downstream effector of CREB in the genistein-triggered
signaling cascade and cell survival, because knockdown of CREB diminished genisteininduced Bcl-2 protein expression and islet cell survival, indicating that CREB-mediated
upregulation of Bcl-2 protein expression plays a major role in genistein promotion of β-cell
survival. It is conceivable that genistein regulates Bcl-2 at the transcriptional levels, given
that the cAMP responsive element (CRE) site present within Bcl-2 promoter plays a major
role in inducing its expression [53]. Indeed, we found that genistein stimulated both cAMPregulated gene expression and Bcl-2 promoter activity in β-cells. Finally, knockdown or
deletion of GPR30 abolished genistein-stimulated CREB phosphorylation in β-cells,
supporting that genistein acts on GPR30 to initiate the antiapoptotic signaling in β-cells.
In summary, we provide both in vitro and in vivo evidence for the first time that genistein
stimulates cAMP signaling via a GPR30-mediated mechanism in β-cells, leading to
improved islet survival. Loss of functional β-cell mass is the key for the deterioration of
glycemic control in both T1D and T2D. In this context, genistein could be a naturally
occurring agent that can be used as an alternative or complementary treatment for diabetes.
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Highlights
•

Phytonutrient genistein activates cAMP signaling via GPR30-mediated
activation of Gαs in pancreatic beta-cells.

•

Genistein ameliorates hyperglycemia in diabetic mice via GPR30.

•

Genistein directly prevents islets from glucolipotoxicity-induced apoptosis via
GPR30-mediated activation of CREB.
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Fig. 1.

Genistein activated cAMP signaling via a Gαs-mediated mechanism in β-cells. (A) AC
activity in INS1 cell plasma membranes preincubated with 100 μM GDPβS (A), Gαs
antibody (Gαs, 1:200 (B), nonimmune IgG, or vehicle (V) for 30 min at 25°C, followed by
stimulation with genistein (G, 2.5 μM), GLP-1 (GLP, 20 nM), forskolin (Fsk, 5μM) or
vehicle for 10 min. Intracellular cAMP levels in INS1 cells (C) or human islets (D)
pretreated with Gαs inhibitor mellittin (M, 5μM) for 30 min, followed by stimulation with
genistein (G, 5μM) for 20 min. Islets were infected with lentiviral particles containing Gαs
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shRNA (Gαsh) or control shRNA (Csh) at MOI of 150. 48 h later, control and infected islets
were either lysed for measuring Gαs and β-actin protein expression to determine the
efficiency of knockdown (E), or incubated with genistein (G, 5μM) for 20 min to measure
intracellular cAMP levels (F). Cyclic AMP levels were normalized to the protein contents,
and expressed as percentage of the control value. Data are mean±SEM (n=4). *, p<0.05 vs.
control.
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Fig. 2.

Genistein stimulation of cAMP production was mediated via GPR30 in β-cells. (A) protein
expression of GPR30 in insulin-secreting cells and islets as determined by western blot
(H=human, M=mouse). (B) Intracellular cAMP levels in INS1 cells preincubated with
vehicle (V) or GPR30 antagonist G15 (5 μM) for 10 min before stimulation with genistein
(G, 5 μM) for 20 min. (C) Knockdown of GPR30 protein expression in INS1 cells
transfected with GPR30 siRNA (I) or scrambled siRNA (S). Images shown were from two
independent transfection experiments. (D) Intracellular cAMP levels in GPR30 siRNA (I) or
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scrambled siRNA (S) transfected cells and exposed to 5 μM genistein or vehicle (V) for 20
min. (E) Intracellular cAMP levels in wild-type (WT) or GPR30−/− (KO) islets incubated
with vehicle (V), genistein (G, 5 μM), or foskolin (F, 1 μM) for 20 min. (F) Western blot for
GPR30 knockout in the islets. Cyclic AMP levels were normalized to the protein contents,
and expressed as percentage of the control value. *, p<0.05 (n=3-4±SEM).
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Fig. 3.

The anti-diabetic effect of genistein in streptozotocin (STZ)-induced obese diabetic mice
was GPR30-dependent. WT or GPR30−/− male mice were fed a standard cow diet (SD), a
high fat diet (HF), or HF supplemented with 0.05% genistein (HF+G) for 4 wks. Mild
hyperglycemia in HF-fed mice was then induced by injection of STZ. Non-fasting blood
glucose levels in WT (A) and GPR30−/− (B) mice were measured at the indicated time
points. Data of intraperitoneal glucose tolerance test (C) and area under the curve (AUC)
calculated using the trapezoidal rule (D) in WT mice. (E) Non-fasting plasma insulin levels

J Nutr Biochem. Author manuscript; available in PMC 2019 August 01.

Luo et al.

Page 22

Author Manuscript

in WT mice. (F) Insulin tolerance test in WT mice at 5 wks after the first STZ injection. (G)
A set of representative micrographs of pancreatic sections stained with insulin antibody. (H)
The β-cell mass determined as described in “Materials and Methods”. (I) Pancreas insulin
contents measured by ELISA. (J) Representative activated caspase-3 (red) and insulin (blue)
double staining of pancreatic sections from WT mice. (K) Quantification of caspase-3positive β-cells expressed as percentage of total insulin-stained cells. Four pancreatic
sections from each mouse with 6 mice per group were evaluated. Data are shown as means ±
SE or mean±SEM (n= 6 mice/group). *, P<0.05.
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Genistein protected INS1 cells and islets from apoptosis. INS1 cells (A, B), mouse (C, D),
or human (E, F) islets were pretreated with or without genistein (G) at indicated
concentrations for 12 h, followed by addition of 0.5 mM palmitate (PA) and 20 mM glucose
(Glu). Cellular apoptosis (A, C, E) and caspase-3 activity (B, D, F) were measured after 72 h
and 48 h of treatment, respectively. Values were expressed as fold of the control. (G) INS1
cells were treated with genistein (G) or vehicle for 48 h. Cellular Bcl-2 protein was detected
by western blot and normalized to β-actin content. (H) INS1cells were co-transfected with
Bcl-2 promoter and control plasmids, followed by addition of genistein for 24 h. Luciferase
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activity in the cell lysates was measured. *, p<0.05 vs. control; #, p<0.05 vs. Glu and PAalone treated islets (n=4±SEM).
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Fig. 5.

The anti-apoptotic effect of genistein was independent of ERα and ERβ. (A) Co-incubation
of human islets with ER inhibitor ICI 182,780 (ICI, 10 μM) blocked the effect of 17βestradiol (E2; 0.1μM), but no that of genistein (Gen, 1 μM), on high glucose (Glu, 20 mM)
and palmitate (PA, 0.5 mM) induced islet apoptosis. (B) Genistein (G, 5 μM) and its nonestrogenic analog daidzein (D, 5 μM) protected human islets from high glucose (Glu; 20
mM) and palmitate (PA; 0.5 mM) induced apoptosis. *, p<0.05 (n= 4±SEM).
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Fig. 6.

The cytoprotecitve effect of genistein on β-cells was dependent of GPR30-mediated
activation of CREB. Western blot analyses of phosphorylated (p-CREB) and total CREB in
INS1 cells (A) or human islets (B) incubated with various concentrations of genistein or
vehicle for 30 min. (C) Total CREB and p-CREB protein levels in INS1 cells pretreated with
PKA inhibitor H89 (10 μM) or vehicle (V) for 30 min, followed by addition of genistein (G,
5 μM) for 30 min. (D) INS1 cells transfected with reporter plasmid pCRE-Luc were
incubated with vehicle or genistein for 24 h. Luciferase activity was measured and
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normalized to the control plasmids in the cell extracts. (E) INS1 cells were transfected with
vehicle (V), scrambled siRNA (S), or siRNA directed against CREB (I) for 48 h. The
efficiency of knockdown in transfected cells was verified by immunoblot analysis of CREB
protein levels. (F) Total and p-CREB levels in control or transfected INS1 cells treated with
genistein (G, 5 μM) or vehicle (V) for 30 min. (G) Bcl-2 protein levels in control or
transfected INS1cells treated with genistein (G, 5 μM) or vehicle (V) for 48 h. (H)
Quantification of apoptosis in control or transfected INS1 cells following treatment with 0.5
mM palmitate (PA) and high glucose (Glu, 20 mM) or vehicle in the presence or absence of
5 μM genistein (G) for 72 h. I. INS1 cells were transfected with scrambled control siRNA
(S) or GPR30 siRNA (I). 48 h later, genistein (5 μM) effect on p-CREB and total CREB
protein contents in cells were measured by western blot. (J) total CREB and p-CREB levels
in WT and GPR30−/− (KO) islets isolated from male mice and treated with or without
genistein (G, 5 μM) for 30 min. (K) Cellular caspase-3 activity in WT and KO islets
incubated with palmitate (PA, 0.5 mM) plus 20 mM glucose (Glu) in the presence or
absence of genistein (G, 5 μM) for 24 h. Values are mean ± SEM (n=4). *, p< 0.05.
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